Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT04725812 · Cedars-Sinai Medical Center · PHASE2 · terminated · last registry update 2023-11-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI moved institutions” | – | Registry record, Cedars-Sinai Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against C5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-20Also stopped (terminated): Alexion Pharmaceuticals, Inc., ALXN2050 (NCT04170023)
- 2024-10-01Also stopped (terminated): Alexion Pharmaceuticals, Inc., Ravulizumab (NCT04743804)
- 2024-09-25Results posted on the registry: Alexion Pharmaceuticals, Inc., Eculizumab (NCT04155424)
- 2024-09-25Also stopped (terminated): Alexion Pharmaceuticals, Inc., Eculizumab (NCT04155424)
- 2024-09-19Phase 3 first posted: Chengdu Suncadia Medicine Co., Ltd., HRS-5965 capsule + Eculizumab Injection (NCT06593938)
- 2024-09-19Results posted on the registry: Regeneron Pharmaceuticals, Cemdisiran + Eculizumab (NCT05131204)
- 2024-08-30Phase 3 first posted: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT06578949)
- 2024-08-12Results posted on the registry: Alexion Pharmaceuticals, Inc., Eculizumab + Ravulizumab (NCT04320602)
- 2024-08-09Results posted on the registry: Alexion Pharmaceuticals, Inc., ALXN2050 (NCT04170023)
- 2024-08-09Also stopped (terminated): Alnylam Pharmaceuticals, Placebo + Cemdisiran (NCT03841448)
- 2024-08-07Phase 3 first posted: Regeneron Pharmaceuticals, Pozelimab + Cemdisiran (NCT06541704)
- 2024-08-06Also stopped (terminated): Andrew Lowy, GL-ONC1 (NCT02714374)
- 2024-06-24Phase 3 first posted: UCB Biopharma SRL, Zilucoplan (NCT06471361)
- 2024-06-07Phase 3 first posted: Alexion Pharmaceuticals, Inc., Danicopan (NCT06449001)
- 2024-05-30Phase 3 first posted: UCB Biopharma SRL, Zilucoplan (NCT06435312)
- 2024-03-26Results posted on the registry: Samsung Bioepis Co., Ltd., SB12 (proposed eculizumab biosimilar) + Soliris (eculizumab) (NCT04058158)
- 2024-03-04Phase 3 first posted: Alexion Pharmaceuticals, Inc., Ravulizumab + Placebo (NCT06291376)
- 2024-02-21Also stopped (withdrawn): Ophthotech Corporation, Zimura + Eylea (NCT03374670)
- 2024-02-09Results posted on the registry: Alexion Pharmaceuticals, Inc., Eculizumab + Placebo (NCT04752566)
- 2024-02-05Results posted on the registry: Alexion Pharmaceuticals, Inc., ALXN1210 (NCT05288816)
- 2024-01-22Results posted on the registry: Alexion Pharmaceuticals, Inc., Ravulizumab + rHuPH20 (NCT05396742)
- 2024-01-03Results posted on the registry: Novartis Pharmaceuticals, iptacopan + Standard of Care (NCT03439839)
- 2023-12-28Results posted on the registry: IVERIC bio, Inc., Avacincaptad Pegol + Sham (NCT04435366)
- 2023-12-12Results posted on the registry: Alexion Pharmaceuticals, Inc., Ravulizumab (NCT04743804)
- 2023-12-08Results posted on the registry: Alnylam Pharmaceuticals, Placebo + Cemdisiran (NCT03841448)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision